11 reports

They' re striving toward this goal through public/ private partnerships like SECURE THE FUTURE, their pioneering $## million HIV/ AIDS program in Africa, and through their patient assistance programs.

  • Bladder Cancer
  • China
  • Demand
  • Trade
  • Sanofi-Synthelabo Inc.

They' re striving toward this goal through public/ private partnerships like SECURE THE FUTURE, their pioneering $## million HIV/ AIDS program in Africa, and through their patient assistance programs.

  • Bladder Cancer
  • China
  • Bristol-Myers Squibb China Inc Ltd
  • Sanofi-Synthelabo Inc.
  • Schering-Plough Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016
  • PIPELINE BY ALTOR BIOSCIENCE CORP, H2 2016

The preliminary results from these collaborations are very encouraging and indicate that ALT-## has substantial potency against a variety of solid tumors as well as HIV infection in experimental models.

  • Bladder Cancer
  • Cancer
  • Interleukin
  • Therapy
  • Altor BioScience Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016

RESULTS OF THE IN VITRO STUDIES DEMONSTRATED THAT AR-## INHIBITS HIV-##, HIV-## AND SIX DRUG RESISTANT HIV-## STRAINS WITH ##% INHIBITORY CONCENTRATIONS (IC##) IN THE RANGE OF ##-## NM (NANOMOLAR) AND MODERATE CYTOTOXICITY (## NM).

  • Bladder Cancer
  • Hospital
  • Therapy
  • United States
  • World
  • MYELODYSPLASTIC SYNDROME

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016’, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog...

  • Bladder Cancer
  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • MedImmune, LLC
  • ALT-803 - DRUG PROFILE

P-MAPA was also under development for the treatment for HIV.

  • Bladder Cancer
  • Oncology
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

For patients with one or more baseline scans, responses were observed in ##/ ## patients (##%) (## PR).

  • Bladder Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative
  • ALT-803 - DRUG PROFILE

TEN PTS (ONE HIV+) REMAIN ON STUDY [## PTS FOR ## MONTHS (M)].

  • Bladder Cancer
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative
  • ALT-803 - DRUG PROFILE

Ten pts (one HIV+) remain on study [## pts for ## months (M)].

  • Bladder Cancer
  • Monoclonal Antibody
  • North America
  • United States
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Bladder Cancer
  • Clinical Trial
  • Oncology
  • World
  • Merck & Co., Inc.
  • ALT-803 - DRUG PROFILE

Its product serves various therapeutic areas such as nonsmall cell lung cancer, HIV infection, parasitic infections and others.

  • Bladder Cancer
  • Therapy
  • United States
  • Company Operations
  • Product Initiative